Journal of Enzyme Inhibition and Medicinal Chemistry (Jan 2021)

Nanovesicles released by OKT3 hybridoma express fully active antibodies

  • Mariantonia Logozzi,
  • Rossella Di Raimo,
  • Francesca Properzi,
  • Stefano Barca,
  • Daniela F. Angelini,
  • Davide Mizzoni,
  • Mario Falchi,
  • Luca Battistini,
  • Stefano Fais

DOI
https://doi.org/10.1080/14756366.2020.1852401
Journal volume & issue
Vol. 36, no. 1
pp. 175 – 182

Abstract

Read online

Recent findings have shown that nanovesicles preparations from either primary immune cells culture supernatants or plasma contain immunoglobulins, suggesting that a natural way of antibody production may be through exosome release. To verify this hypothesis, we used the OKT3 hybridoma clone, which produces a murine IgG2a monoclonal antibody used to reduce rejection in patients undergoing organ transplantation. We showed exosome-associated immunoglobulins in hybridoma supernatants, by Western blot, nanoscale flow cytometry and immunocapture-based ELISA. The OKT3-exo was also being able to trigger cytokines production in both CD4 and CD8 T cells. These results show that nanovesicles contain immunoglobulin and could be used for immunotherapy. These data could lead to a new approach to improve the effectiveness of therapeutic antibodies by exploiting their natural property to be expressed on nanovesicle membrane, that probably render them more stable and as a consequence more capable to interact with their specific ligand in the best way.

Keywords